[go: up one dir, main page]

WO2007095185A3 - Variants in complement regulatory genes predict age-related macular degeneration - Google Patents

Variants in complement regulatory genes predict age-related macular degeneration Download PDF

Info

Publication number
WO2007095185A3
WO2007095185A3 PCT/US2007/003696 US2007003696W WO2007095185A3 WO 2007095185 A3 WO2007095185 A3 WO 2007095185A3 US 2007003696 W US2007003696 W US 2007003696W WO 2007095185 A3 WO2007095185 A3 WO 2007095185A3
Authority
WO
WIPO (PCT)
Prior art keywords
variants
macular degeneration
related macular
regulatory genes
complement regulatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/003696
Other languages
French (fr)
Other versions
WO2007095185A2 (en
Inventor
Rando L Allikmets
Gregory S Hageman
Michael C Dean
Albert M Gold
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Iowa Research Foundation UIRF
Columbia University in the City of New York
National Institutes of Health NIH
Original Assignee
University of Iowa Research Foundation UIRF
Columbia University in the City of New York
National Institutes of Health NIH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Iowa Research Foundation UIRF, Columbia University in the City of New York, National Institutes of Health NIH filed Critical University of Iowa Research Foundation UIRF
Priority to JP2008554415A priority Critical patent/JP5290772B2/en
Priority to EP07750527A priority patent/EP1989319A4/en
Priority to NZ570431A priority patent/NZ570431A/en
Priority to AU2007215218A priority patent/AU2007215218B2/en
Priority to CA002638916A priority patent/CA2638916A1/en
Publication of WO2007095185A2 publication Critical patent/WO2007095185A2/en
Priority to IL193396A priority patent/IL193396A/en
Anticipated expiration legal-status Critical
Publication of WO2007095185A3 publication Critical patent/WO2007095185A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Methods for identifying a subject at risk for developing AMD are disclosed, as are kits which can be used to practice the methods. The methods include identifying specific protective or risk polymorphisms or genotypes from the subject's genetic material, including polymorphisms in the BF, C2 and/or CFH genes. Microarrays and kits for use in these methods are also provided.
PCT/US2007/003696 2006-02-13 2007-02-13 Variants in complement regulatory genes predict age-related macular degeneration Ceased WO2007095185A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2008554415A JP5290772B2 (en) 2006-02-13 2007-02-13 Mutants in complement regulatory genes predict age-related macular degeneration
EP07750527A EP1989319A4 (en) 2006-02-13 2007-02-13 COMPLEMENT REGULATION GENE VARIANTS FOR PREDICTING AGE-RELATED MACULAR DEGENERATION
NZ570431A NZ570431A (en) 2006-02-13 2007-02-13 Variants in complement regulatory genes predict age-related macular degeneration
AU2007215218A AU2007215218B2 (en) 2006-02-13 2007-02-13 Variants in complement regulatory genes predict age-related macular degeneration
CA002638916A CA2638916A1 (en) 2006-02-13 2007-02-13 Variants in complement regulatory genes predict age-related macular degeneration
IL193396A IL193396A (en) 2006-02-13 2008-08-12 Variants in complement regulatory genes to predict age-related macular degeneration

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77298906P 2006-02-13 2006-02-13
US60/772,989 2006-02-13

Publications (2)

Publication Number Publication Date
WO2007095185A2 WO2007095185A2 (en) 2007-08-23
WO2007095185A3 true WO2007095185A3 (en) 2008-09-25

Family

ID=38372062

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/003696 Ceased WO2007095185A2 (en) 2006-02-13 2007-02-13 Variants in complement regulatory genes predict age-related macular degeneration

Country Status (8)

Country Link
EP (1) EP1989319A4 (en)
JP (1) JP5290772B2 (en)
CN (1) CN101421409A (en)
AU (1) AU2007215218B2 (en)
CA (1) CA2638916A1 (en)
IL (1) IL193396A (en)
NZ (1) NZ570431A (en)
WO (1) WO2007095185A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8012683B2 (en) 2006-02-13 2011-09-06 University Of Iowa Research Foundation Variants in complement regulatory genes predict age-related macular degeneration
WO2010127176A2 (en) * 2009-04-29 2010-11-04 Massachusetts Eye And Ear Infirmary Methods and compositions for prognosing detecting age-related macular degeneration
EP2963128A1 (en) 2009-07-10 2016-01-06 The Regents of the University of Michigan Compositions and methods for diagnosing and treating macular degeneration
US20110104154A1 (en) * 2009-10-30 2011-05-05 Alcon Research, Ltd. Single nucleotide polymorphisms and genes associated with age-related macular degeneration
US9056874B2 (en) 2012-05-04 2015-06-16 Novartis Ag Complement pathway modulators and uses thereof
CN102707068B (en) * 2012-05-31 2015-03-18 北京大学 Application of complement factor H (CFH) to genetic expression products of methamphetamine (METH) addiction patient
JP6387391B2 (en) 2013-03-14 2018-09-05 ノバルティス アーゲー 2- (1H-Indol-4-ylmethyl) -3H-imidazo [4,5-b] pyridine-6-carbonitrile derivatives as complement factor B inhibitors useful for the treatment of ophthalmic diseases
EP3089963A1 (en) 2013-10-30 2016-11-09 Novartis AG 2-benzyl-benzimidazole complement factor b inhibitors and uses thereof
EP3102701A1 (en) * 2014-02-07 2016-12-14 Novartis AG Impact of genetic factors on disease progression and response to anti-c5 antibody in geographic atrophy
WO2016100745A2 (en) * 2014-12-19 2016-06-23 Children's Hospital Medical Center Methods and compositions related to transplant-associated thrombotic microangiopathy
CN109082460B (en) * 2018-09-27 2021-07-13 领航基因科技（杭州）有限公司 Non-competitive probe design method, detection method and application applied to SNP typing
KR102414152B1 (en) * 2020-08-20 2022-06-29 (주)지놈오피니언 Biomarker for diagnosing age-related macular degeneration and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU575586B2 (en) 1983-09-02 1988-08-04 Syngene, Inc. Oligonucleotide synthesis employing primer with oxidzable substituents in system
GB8810400D0 (en) 1988-05-03 1988-06-08 Southern E Analysing polynucleotide sequences
US5554501A (en) 1992-10-29 1996-09-10 Beckman Instruments, Inc. Biopolymer synthesis using surface activated biaxially oriented polypropylene
DE69503126T2 (en) 1994-05-05 1998-11-12 Beckman Instruments Inc REPETITIVE OLIGONUCLEOTIDE MATRIX
US5985567A (en) 1997-08-15 1999-11-16 Beckman Coulter, Inc. Hybridization detection by pretreating bound single-stranded probes
US6013789A (en) 1998-02-20 2000-01-11 Beckman Coulter, Inc. Covalent attachment of biomolecules to derivatized polypropylene supports
WO2006062716A2 (en) * 2004-11-18 2006-06-15 Yale University Methods and compositions for treating ocular disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ABRERA-ABELEDA M.A.: "Variations In The Complement Regulatory Genes Factor H and Factor H Related 5 Are Associated With Membranoproliferative Glomerulonephritis Type II", J. MED. GENET., vol. 43, 2006, pages 582 - 589, XP008102582 *
BOERHINGER MANNHEIM: "Biochemical Catalog, Non-Radioactive Labeling and Detection of Nucleic Acids", 1997 *
DATABASE SNP [online] "Cluster Report", XP008138645, Database accession no. (rs641153) *

Also Published As

Publication number Publication date
WO2007095185A2 (en) 2007-08-23
IL193396A0 (en) 2009-05-04
JP2009526524A (en) 2009-07-23
EP1989319A4 (en) 2009-11-11
IL193396A (en) 2013-03-24
EP1989319A2 (en) 2008-11-12
CN101421409A (en) 2009-04-29
JP5290772B2 (en) 2013-09-18
AU2007215218B2 (en) 2013-09-19
NZ570431A (en) 2011-12-22
AU2007215218A1 (en) 2007-08-23
CA2638916A1 (en) 2007-08-23

Similar Documents

Publication Publication Date Title
WO2007095185A3 (en) Variants in complement regulatory genes predict age-related macular degeneration
MX2007009565A (en) Methods and reagents for treatment and diagnosis of age-related macular degeneration.
IL182837A0 (en) Methods, assays and compositions for treating retinol-related diseases
WO2009059317A3 (en) Predicting amd with snps within or near c2, factor b, plekha1, htra1, prelp, or loc387715
GB2477868A (en) Methods and systems for incorporating multiple environmental and genetic risk factors
PT2121963E (en) Methods for identifying a strain isolated from a clinical sample at the species and/or subspecies level
MY154507A (en) Gene Controlling Shell Phenotype in Palm
WO2008103299A3 (en) Methods and compositions for prognosing, detecting, and treating age-related macular degeneration
WO2007120975A8 (en) Variants in complement regulatory genes predict age-related macular degeneration
WO2009082743A3 (en) Genetic markers for schizophrenia and bipolar disorder
WO2010075519A3 (en) Allelic variants associated with advanced age-related macular degeneration
ZA200710910B (en) Methods for the assessment of risk of developing lung cancer using analysis of genetic polymorphisms
WO2006037462A3 (en) Cancer markers
WO2008144599A3 (en) Genetic markers for efficacy of iloperidone in the treatment of psychotic symptoms
WO2008010083A3 (en) Method for prognosing osteoporosis phenotypes
WO2006099259A3 (en) Novel missense mutations and single nucleotide polymorphisms in the rabphillin-3a-like gene and uses thereof
Soltyszewski et al. Y-chromosomal haplotypes for the AmpFlSTR Yfiler PCR Amplification Kit in a population sample from Central Poland
WO2009060210A8 (en) Predictive test for adult dog body size
WO2007006862A3 (en) Method and kit for detecting a risk of coronary heart disease
WO2008131367A3 (en) Methods of diagnosing alzheimer's disease and markers identified by set association
WO2002080755A3 (en) Kits and methods for assessing oxidative stress
WO2005052180A3 (en) Ntrk1 genetic markers associated with progression of alzheimer’s disease
GB2489180A (en) Method of predicting capecitabine toxicity
WO2011130636A3 (en) Methods and compositions for identifying mutations in cancer related genes
WO2007046094A3 (en) Schizophrenia associated genes and markers

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2638916

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 193396

Country of ref document: IL

Ref document number: 2008554415

Country of ref document: JP

Ref document number: 570431

Country of ref document: NZ

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007215218

Country of ref document: AU

REEP Request for entry into the european phase

Ref document number: 2007750527

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007750527

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 4680/CHENP/2008

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2007215218

Country of ref document: AU

Date of ref document: 20070213

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 200780012906.3

Country of ref document: CN